Neurodegenerative Drugs

Neurodegenerative Drugs Market Outlook

The global neurodegenerative drugs market is projected to reach approximately USD 36 billion by 2035, with a compound annual growth rate (CAGR) of around 7% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as the growing aging population worldwide. Additionally, advancements in pharmaceutical research, including the development of novel therapeutic molecules and biologics, are expected to significantly contribute to market expansion. Furthermore, an increasing focus on early diagnosis and treatment options has resulted in a rising demand for innovative drugs that effectively manage neurodegenerative conditions. The push for personalized medicine and the integration of digital health solutions further amplify the growth potential of the neurodegenerative drugs market.

Growth Factor of the Market

Several factors are contributing to the rapid growth of the neurodegenerative drugs market. One of the most significant factors is the rising incidence of neurodegenerative diseases, which are becoming increasingly common in an aging population. As people live longer, the prevalence of conditions such as Alzheimer's and Parkinson's disease continues to rise, leading to greater demand for effective treatment options. Moreover, continuous advancements in drug development technologies and research methodologies are fostering innovation in the creation of new pharmaceutical products aimed at treating these debilitating conditions. Increased investment in research and development by pharmaceutical companies is also paving the way for the introduction of effective therapies, which boosts market growth. Furthermore, supportive government regulations and incentives for drug development and approval are enhancing the attractiveness of this market for investors and stakeholders alike. The growing awareness and understanding of neurodegenerative disorders among healthcare professionals and the general public are also contributing to the growing market as more individuals seek treatment options.

Key Highlights of the Market

• The market is expected to grow at a CAGR of 7% between 2025 and 2035.
• North America is anticipated to hold the largest market share, driven by advanced healthcare infrastructure.
• The Alzheimer's disease segment is projected to account for a significant portion of the market due to its high prevalence.
• Cholinesterase inhibitors are expected to dominate the product type segment as they are the first line of treatment for Alzheimer's disease.
• Online pharmacies are rapidly gaining popularity as a distribution channel, particularly due to the convenience they offer.

By Product Type

Cholinesterase Inhibitors:

Cholinesterase inhibitors are among the most widely prescribed medications in the treatment of Alzheimer's disease. These drugs work by blocking the enzyme that breaks down acetylcholine, a neurotransmitter that plays a crucial role in memory and cognition. By increasing acetylcholine levels, cholinesterase inhibitors can help improve cognitive function and slow the progression of symptoms in patients. The recognition of these benefits has resulted in a robust market for this class of drugs, making them essential for managing Alzheimer's disease and significantly influencing the overall neurodegenerative drugs market.

NMDA Receptor Antagonists:

NMDA receptor antagonists, such as memantine, are another critical segment in the neurodegenerative drugs market. These medications function by modulating glutamate, a neurotransmitter involved in learning and memory. By preventing excessive activation of NMDA receptors, these drugs help protect neurons from damage and improve cognitive function in Alzheimer's patients. The unique mechanism of action of NMDA receptor antagonists, combined with their effectiveness in treating moderate to severe Alzheimer's disease, has contributed to their increasing adoption in clinical practice, driving the market's growth.

Dopamine Agonists:

Dopamine agonists play a vital role in the management of Parkinson's disease by stimulating dopamine receptors in the brain. Since Parkinson's disease is characterized by a deficiency of dopamine, these medications help alleviate symptoms such as tremors, rigidity, and bradykinesia. The market for dopamine agonists has been expanding due to the growing number of diagnosed patients and the demand for effective symptom management options. Furthermore, the emerging trend of using dopamine agonists in combination therapies is expected to create new growth opportunities for this segment.

Antioxidants:

Antioxidants are gaining traction in the neurodegenerative drugs market as potential therapeutic agents for various neurodegenerative conditions. These compounds work by combating oxidative stress, which is believed to contribute to the pathogenesis of diseases such as Alzheimer's and Parkinson's. Research has shown that certain antioxidants may help protect neurons and improve cognitive function, leading to an increase in their usage in clinical settings. As scientific understanding of the role of oxidative stress in neurodegeneration advances, the market for antioxidant-based therapies is likely to witness sustained growth.

Others:

The "Others" category encompasses a range of therapeutic agents that do not fall into the main classifications of neurodegenerative drugs. This includes newer compounds and experimental drugs that are under investigation for their efficacy in treating conditions like amyotrophic lateral sclerosis (ALS) and Huntington's disease. As researchers continue to explore various pharmacological pathways to target neurodegenerative diseases, this segment is expected to expand, providing additional treatment options and driving overall market growth.

By Application

Alzheimer's Disease:

Alzheimer's disease is the most common neurodegenerative disorder and is expected to account for a significant share of the overall market. The increasing prevalence of Alzheimer's, driven by an aging population and lifestyle factors, has led to heightened demand for effective therapies that can address the cognitive decline associated with the condition. With advancements in drug development, numerous new treatments are being introduced, focusing on both symptom management and disease modification. As ongoing research continues to yield promising results, the Alzheimer's disease segment is anticipated to experience substantial growth in the coming years.

Parkinson's Disease:

Parkinson's disease represents another major application area within the neurodegenerative drugs market. The rising awareness and diagnosis rates of Parkinson's have fueled the demand for effective treatment options aimed at alleviating motor and non-motor symptoms. As the understanding of the disease's pathophysiology improves, new therapeutic options, including gene therapy and neuroprotective agents, are being explored. The growing market for Parkinson's disease treatments is expected to be driven by the need for better symptom control and improvement in the quality of life for patients.

Huntington's Disease:

Huntington's disease is a genetic neurodegenerative disorder characterized by progressive motor dysfunction and cognitive decline. Although less prevalent than Alzheimer's and Parkinson's, it presents significant therapeutic challenges, leading to a growing interest in research and drug development. The market for Huntington's disease drugs is likely to grow as new treatments are being developed, particularly those targeting the underlying genetic causes of the disease. As more patients are diagnosed and awareness of Huntington's disease increases, this segment is expected to expand significantly.

Amyotrophic Lateral Sclerosis:

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative condition that affects motor neurons, leading to muscle weakness and eventual paralysis. The complexity of ALS has resulted in relatively limited treatment options; however, the demand for effective therapies remains high. Ongoing research efforts to understand the mechanisms driving ALS will likely lead to innovations in drug development, further stimulating growth in this application segment. As awareness of ALS increases and new therapies come to market, the segment is expected to witness notable expansion.

Others:

The "Others" application category includes various rare neurodegenerative diseases that require dedicated therapeutic approaches. This segment encompasses conditions such as multiple sclerosis and frontotemporal dementia, which, although less common, still represent significant unmet medical needs. The development of targeted therapies for these diseases is gaining momentum as researchers identify new biological pathways and mechanisms to explore. As innovative treatment options emerge, the growth potential of the "Others" application segment will become increasingly relevant in the neurodegenerative drugs market.

By Distribution Channel

Hospitals:

Hospitals play a crucial role as a distribution channel for neurodegenerative drugs, particularly in more severe cases where patients require specialized treatments and monitoring. The presence of healthcare professionals, diagnostic facilities, and integrated care systems enhances the ability to provide comprehensive management of neurodegenerative diseases. As hospitals increasingly adopt advanced treatment protocols and therapies, the market share for this distribution channel is expected to remain significant, with a steady rise in demand for neurodegenerative medications.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for neurodegenerative drugs, providing convenient access for patients and caregivers. The growing number of patients diagnosed with neurodegenerative diseases has led to increased demand for prescription medications available at these outlets. Retail pharmacies' ability to offer personalized consultations and medication management services further enhances their role in the treatment journey of patients with neurodegenerative disorders. As patients seek greater convenience and accessibility, the share of retail pharmacies in the distribution of neurodegenerative drugs is likely to grow.

Online Pharmacies:

Online pharmacies have emerged as a transformative distribution channel in the neurodegenerative drugs market, driven by the increasing preference for digital health solutions and the need for convenience. The ability to order medications online and receive home delivery has gained popularity among patients, especially those with mobility issues or those living in remote areas. As more patients become comfortable with online shopping and telehealth services, the online pharmacy segment is projected to grow significantly, providing a valuable alternative to traditional distribution channels.

Drug Stores:

Drug stores represent another important distribution channel for neurodegenerative medications, often serving as local hubs for patients seeking prescription drugs. These establishments offer a range of products and services, including patient counseling and health education. The proximity of drug stores to communities plays a pivotal role in facilitating access to neurodegenerative drugs, particularly for patients who may face challenges in visiting hospitals or pharmacies. As the demand for neurodegenerative medications continues to rise, drug stores are expected to maintain a competitive position in the market.

Others:

The "Others" distribution channel category includes various non-traditional outlets such as specialty pharmacies, compounding pharmacies, and healthcare provider offices. These channels often cater to specific patient needs and provide tailored solutions for neurodegenerative drug access. Specialty pharmacies, in particular, focus on managing complex therapies and ensuring proper medication adherence, which is essential for patients with chronic conditions. As the landscape of drug distribution evolves and more tailored solutions emerge, this segment is expected to see increased activity and relevance in the overall neurodegenerative drugs market.

By Ingredient Type

Levodopa:

Levodopa is one of the most commonly prescribed medications for the management of Parkinson's disease. It works by replenishing dopamine levels in the brain and alleviating motor symptoms associated with the condition. The efficacy of levodopa has established it as a cornerstone in Parkinson's therapy, and its market presence is bolstered by the increasing number of Parkinson's diagnoses worldwide. As research continues to explore optimal combinations and formulations, the demand for levodopa is expected to remain strong, contributing significantly to the overall neurodegenerative drugs market.

Memantine:

Memantine is a cornerstone in the treatment of moderate to severe Alzheimer's disease, functioning as an NMDA receptor antagonist that modulates glutamatergic activity. The growing awareness of Alzheimer's and the increasing prevalence of the condition have driven the demand for effective treatment options like memantine. Furthermore, ongoing clinical trials exploring the drug's potential in combination with other therapies are likely to enhance its market position and expand its use among healthcare providers, thereby positively impacting the neurodegenerative drugs market.

Rivastigmine:

Rivastigmine is another significant medication within the neurodegenerative drugs market, primarily used to treat Alzheimer's and Parkinson's disease dementia. As a cholinesterase inhibitor, rivastigmine's ability to enhance cholinergic neurotransmission makes it a key player in symptomatic management. The growing body of clinical evidence supporting its effectiveness and safety profile has led to its increased acceptance among healthcare professionals and patients alike. This, in turn, is expected to drive the rivastigmine segment's growth over the coming years as more patients seek effective therapies.

Donepezil:

Donepezil is widely recognized as a first-line treatment for Alzheimer's disease, acting as a reversible acetylcholinesterase inhibitor. Its ability to improve cognitive function and delay disease progression has made it a preferred choice for many healthcare providers. The extensive clinical experience with donepezil, along with its favorable side effect profile, has resulted in a robust market presence. As more patients are diagnosed with Alzheimer's and seek effective management options, the demand for donepezil is anticipated to remain strong, further reinforcing its position in the neurodegenerative drugs market.

Others:

The "Others" ingredient type category encompasses a range of medications and compounds utilized in the treatment of various neurodegenerative diseases. This segment includes emerging therapies and investigational drugs that target specific pathways associated with neurodegeneration. As research continues to uncover novel mechanisms and treatment strategies, the "Others" category is expected to expand, providing new options for patients and potentially transforming the neurodegenerative drugs market landscape. As these innovative therapies gain traction, their impact on patient outcomes and overall market dynamics may be significant.

By Region

The North American neurodegenerative drugs market is poised to dominate, driven by advanced healthcare infrastructure, a well-established pharmaceutical industry, and a high prevalence of neurodegenerative diseases. The United States, in particular, accounts for a substantial share of the market due to the increasing aging population and rising healthcare expenditure. Additionally, continuous investments in research and development, alongside a supportive regulatory environment, are expected to propel market growth in North America. The region is projected to witness a CAGR of approximately 7.5% from 2025 to 2035, solidifying its position as a leading market for neurodegenerative drugs.

In Europe, the neurodegenerative drugs market is also expected to experience significant growth, with countries such as Germany, France, and the United Kingdom contributing considerably to market expansion. The aging population in Europe, combined with increased awareness and diagnosis of neurodegenerative diseases, has led to heightened demand for effective treatment options. Furthermore, the presence of numerous leading pharmaceutical companies and research institutions within the region is facilitating innovation and the development of novel therapies. As the European market continues to evolve, it is anticipated to follow a steady growth trajectory, further establishing itself as a key player in the global neurodegenerative drugs market.

Opportunities

The neurodegenerative drugs market presents numerous opportunities for growth, particularly as research advances and new treatment modalities emerge. The increasing understanding of the underlying mechanisms of neurodegenerative diseases can lead to the development of targeted therapies that address the root causes of conditions like Alzheimer's, Parkinson's, and Huntington's disease. Furthermore, technological advancements in drug delivery systems, such as nanotechnology and gene therapy, hold the potential to enhance treatment efficacy and improve patient compliance. As these innovations come to fruition, they are likely to reshape the market landscape and create new avenues for pharmaceutical companies to explore.

Another prominent opportunity lies in the expansion of personalized medicine within the neurodegenerative drugs market. By tailoring treatment approaches to individual patient profiles, healthcare providers can optimize therapeutic outcomes and enhance quality of life for patients. The incorporation of genetic testing and biomarker identification can help determine the most effective treatment strategies for specific patient populations. As healthcare systems worldwide increasingly adopt personalized medicine principles, the neurodegenerative drugs market is expected to experience a shift toward more patient-centric approaches, driving demand for innovative solutions and therapies.

Threats

Despite its growth potential, the neurodegenerative drugs market faces several threats that could hinder progress. One primary concern is the rising cost of drug development and the lengthy regulatory approval processes that can delay the introduction of new therapies. As pharmaceutical companies invest significant resources into research and clinical trials, the financial burden may deter smaller firms from entering the market and limit innovation. Additionally, market dynamics can be influenced by the emergence of generic alternatives, which may lead to price erosion and reduced profitability for established players. Furthermore, the complexity of neurodegenerative diseases presents challenges in research and development, as not all therapeutic candidates yield successful outcomes in clinical trials, resulting in potential setbacks and losses.

The growing competition in the neurodegenerative drugs market also poses a threat to established companies. As more players enter the market, the landscape becomes increasingly crowded, leading to heightened competition for market share. Additionally, the potential for disruptive technologies and new treatment modalities, including biologics and personalized therapies, could challenge traditional approaches to treatment. Companies must continuously innovate and adapt to maintain their competitive edge, which may require significant investments in research and development. As the market evolves, companies must navigate these challenges to remain relevant and capitalize on growth opportunities.

Competitor Outlook

• Biogen Inc.
• Novartis AG
• Eli Lilly and Company
• Roche Holding AG
• Amgen Inc.
• Merck & Co., Inc.
• AbbVie Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Acadia Pharmaceuticals Inc.
• Galaxy Therapeutics
• Axovant Gene Therapies Ltd.
• Alnylam Pharmaceuticals, Inc.

The competitive landscape of the neurodegenerative drugs market is characterized by the presence of several key players, each striving to innovate and capture market share through the development of effective therapies. Major pharmaceutical companies, such as Biogen, Novartis, and Eli Lilly, are at the forefront of research and development efforts, focusing on addressing unmet medical needs in neurodegenerative diseases. With robust pipelines and a commitment to advancing drug discovery, these companies are actively competing to bring novel treatments to market. Additionally, the collaboration between academic institutions and pharmaceutical companies is fostering an environment of innovation, allowing for the exploration of new treatment modalities and enhanced understanding of complex neurodegenerative conditions.

Notably, companies like Roche and Amgen are leveraging their expertise in biologics and gene therapy to explore innovative approaches for the treatment of neurodegenerative diseases. Their investments in research and development, coupled with strategic partnerships, are expected to facilitate the introduction of groundbreaking therapies that can significantly impact patient care. Furthermore, the emergence of smaller biotech firms, including Axovant Gene Therapies and Acadia Pharmaceuticals, is contributing to the competitive landscape by introducing specialized treatments and targeting niche markets within the neurodegenerative drugs segment. These companies are often agile and focused on specific disease areas, allowing them to quickly adapt to evolving market dynamics and capitalize on emerging opportunities.

In summary, the neurodegenerative drugs market is witnessing intense competition as major corporations and emerging players alike strive to innovate and address the growing demand for effective therapies. The competitive landscape is continuously evolving, driven by advancements in research, increasing collaboration, and a focus on patient-centric approaches. As the market matures, companies will need to differentiate themselves through their product offerings and capitalize on growth opportunities to maintain their positions as leaders in the neurodegenerative drugs sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Biogen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 H. Lundbeck A/S
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Galaxy Therapeutics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Acadia Pharmaceuticals Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Axovant Gene Therapies Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Alnylam Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Otsuka Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Neurodegenerative Drugs Market, By Application
    • 6.1.1 Alzheimer's Disease
    • 6.1.2 Parkinson's Disease
    • 6.1.3 Huntington's Disease
    • 6.1.4 Amyotrophic Lateral Sclerosis
    • 6.1.5 Others
  • 6.2 Neurodegenerative Drugs Market, By Product Type
    • 6.2.1 Cholinesterase Inhibitors
    • 6.2.2 NMDA Receptor Antagonists
    • 6.2.3 Dopamine Agonists
    • 6.2.4 Antioxidants
    • 6.2.5 Others
  • 6.3 Neurodegenerative Drugs Market, By Ingredient Type
    • 6.3.1 Levodopa
    • 6.3.2 Memantine
    • 6.3.3 Rivastigmine
    • 6.3.4 Donepezil
    • 6.3.5 Others
  • 6.4 Neurodegenerative Drugs Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Neurodegenerative Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Neurodegenerative Drugs market is categorized based on

By Product Type

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Dopamine Agonists
• Antioxidants
• Others

By Application

• Alzheimer's Disease
• Parkinson's Disease
• Huntington's Disease
• Amyotrophic Lateral Sclerosis
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Levodopa
• Memantine
• Rivastigmine
• Donepezil
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Biogen Inc.
• Novartis AG
• Eli Lilly and Company
• Roche Holding AG
• Amgen Inc.
• Merck & Co., Inc.
• AbbVie Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Acadia Pharmaceuticals Inc.
• Galaxy Therapeutics
• Axovant Gene Therapies Ltd.
• Alnylam Pharmaceuticals, Inc.